Adherium (ASX:ADRDB) Marketable Securities: A$0.00 Mil (As of Dec. 2025)


ASX:ADRDB Adherium Ltd ASX:ADRDB
8 GF Score
Price A$0.20
GF Value A$0.35
Valuation Possible Value Trap
! 8 Warning Signs
View Full Analysis

What is Adherium Marketable Securities?

Adherium ASX:ADRDB 8 Marketable Securities is A$0.00 Mil as of Dec. 2025. GuruFocus rates ASX:ADRDB with a GF Score™ of 8/100 and a GF Value™ of A$0.35 (Possible Value Trap). The stock has 8 warning signs investors should review.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. Adherium's Marketable Securities for the quarter that ended in Dec. 2025 was A$0.00 Mil.

Adherium  (ASX:ADRDB) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

Adherium Marketable Securities Related Terms

Adherium Marketable Securities Historical Data

* Premium members only.

The historical data trend for Adherium's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Adherium Marketable Securities Chart

Adherium Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Marketable Securities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Adherium Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
ASX:ADRDB
8GF Score
Adherium Ltd ASX:ADRDB
Marketable Securities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Adherium Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Frequently Asked Questions Learn more about Marketable Securities →
What does a Marketable Securities of A$0.00 Mil mean?
Adherium (ASX:ADRDB) has a Marketable Securities of A$0.00 Mil as of Dec. 2025. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Adherium and its competitors.
Is Adherium's Marketable Securities too high?
Adherium's current Marketable Securities is A$0.00 Mil. Overall, Adherium has a GF Score™ of 8/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Adherium's Marketable Securities compare to ABT and SYK?
Adherium's Marketable Securities of A$0.00 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Marketable Securities for a Medical Devices & Instruments company?
A good Marketable Securities depends on the Medical Devices & Instruments industry context. However, Marketable Securities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Marketable Securities mean?
A high Marketable Securities can signal that a stock is expensive relative to its fundamentals. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Adherium and its competitors. Adherium's current Marketable Securities is A$0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Adherium stock overvalued right now?
Based on GuruFocus' analysis, Adherium (ASX:ADRDB) is currently considered Possible Value Trap. The stock's GF Value™ is A$0.35, compared to a current price of A$0.20 — trading 42.9% below its estimated fair value. The current Marketable Securities is A$0.00 Mil. Adherium's overall GF Score™ is 8/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Marketable Securities calculated?
Marketable Securities is calculated from a company's financial statements. For Adherium (ASX:ADRDB), the current Marketable Securities is A$0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Adherium (ASX:ADRDB) Overvalued in 2026?

Based on GuruFocus' analysis, Adherium stock appears to be undervalued. The current stock price of A$0.20 is trading 42.9% below its estimated GF Value™ of A$0.35. GuruFocus considers Adherium to be Possible Value Trap.

Key valuation signals for ASX:ADRDB:

  • Marketable Securities: A$0.00 Mil
  • GF Value™: A$0.35 vs. price of A$0.20 (42.9% below fair value)
  • GF Score™: 8/100 with 8 warning signs

No single metric tells the full story. See the ASX:ADRDB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Adherium Business Description

Other Exchanges ADRMF:USA
Address 447 Collins Street, Level 5, Melbourne, VIC, AUS, 3000
Adherium Ltd is engaged in the development, manufacture, and supply of its Hailie digital health technologies that address sub-optimal medication use and improve health outcomes in chronic disease. It is an international Respiratory eHealth company focused on patient medication adherence, remote monitoring, and data management solutions for patients, payers, and providers. Its geographically segments include New Zealand and Australia, Europe, North America, and Asia. The majority of its revenue comes from Europe.
8GF Score

Get the complete analysis for ASX:ADRDB

Marketable Securities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.20
Price
A$0.35
GF Value